Schrodinger SDGR Drug discovery — Unsatisfied performance obligation

Similar metrics at other companies

BEProduct — Unsatisfied performance obligations

$441.1M—

AMERemaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied

$684.7M+23.3%

AJGRemaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied

$986M—

LHXRemaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied

$40.7B+22.6%

BEService — Unsatisfied performance obligations

$51.5M—

MSCIRemaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied

$1.17B+23.0%

Other financials

Income statement

See full

Revenue$58.6M-1.6%

Gross profit$29.5M-5.1%

Operating income-$48.8M+4.1%

Net income-$60.0M-0.4%

EPS (diluted)-$0.81+1.2%

Balance sheet

See full

Cash & equivalents$267.7M-20.7%

Total debt$107.0M-7.9%

Total equity$313.5M-16.1%

Total assets$634.2M-14.6%

Cash flow

See full

Operating cash flow-$14.8M-110%

CapEx$2.5M+321%

Free cash flow-$17.3M-112%

Valuation

See full

Market cap$1.15B-23.7%

Enterprise value$984.71M-23.1%

P/S4.5×-2.0×

Profitability

See full

Gross margin55.3%-7.3pp

Operating margin-64.7%-12.0pp

Net margin-68.5%—

FCF margin9.6%+5.1pp

Returns & leverage

See full

Return on equity-45.7%—

Debt / equity0.3×0.0×

Current ratio2.7×-0.7×

Where this comes from

Reported directly by Schrodinger in its filing.

Tagged under the XBRL concept us-gaap:RevenueRemainingPerformanceObligation.

The official record: Schrodinger’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schrodinger's drug discovery — unsatisfied performance obligation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Schrodinger's drug discovery — unsatisfied performance obligation?: Schrodinger (SDGR) reported drug discovery — unsatisfied performance obligation of $112.38M in Q1 2026.
What does drug discovery — unsatisfied performance obligation mean?: This metric quantifies the aggregate transaction price allocated to performance obligations that are partially or fully unsatisfied at the end of the reporting period. It reflects the volume of work remaining under existing drug discovery contracts and helps investors assess the company's future service delivery commitments.